中国医院用药评价与分析2025，Vol.25Issue(2)：220-222,226,4.DOI:10.14009/j.issn.1672-2124.2025.02.020
372例患者新型抗肿瘤药物使用合理性分析
Application Rationality of Novel Antitumor Drugs in 372 Patients
摘要
Abstract
OBJECTIVE:To probe into the rationality of clinical application of novel antitumor drugs in the hospital.METHODS:Retrospective investigation and analysis were conducted to summarize the drug application characteristics of patients with novel antitumor drugs in the hospital from Jan.1st,2022 to Jan.1st,2024 through hospital information system(HIS)system,the rationality and drug application characteristics were evaluated and analyzed.RESULTS:A total of 372 patients were enrolled,and 1 473 cases of novel antitumor drugs were used,among which 192 cases were irrational,and the irrational rate was 13.03％.The main manifestations were incomplete gene detection(75 cases,5.09％),application of novel antitumor drugs without evidence-based medical evidence(34 cases,2.31％),inappropriate usage and dosage(45 cases,3.05％)and improper drug combination(38 cases,2.58％).CONCLUSIONS:The clinical application of novel antitumor drugs in the hospital is partly irrational.The hospital should establish regulations and regularly organize special training for clinicians to standardize the prescription behavior and for pharmacists to strengthen the prescription review and intervention,so as to improve the rational application of novel antitumor drugs in clinical practice.关键词
新型抗肿瘤药物/用药合理性/基因检测/超适应证Key words
Novel antitumor drugs/Drug application rationality/Genetic testing/Off-label indications分类
医药卫生引用本文复制引用
施嫣嫣,黄玉宇..372例患者新型抗肿瘤药物使用合理性分析[J].中国医院用药评价与分析,2025,25(2):220-222,226,4.基金项目
国家中医药管理局"十二五"重点专科培育项目(No.苏中医政〔2012〕13 号) （No.苏中医政〔2012〕13 号）
